（文章来源：证券日报） 证券日报网讯 12月11日，安必平在互动平台回答投资者提问时表示，股票价格受宏观经济环境、市场 行情、板块热点等多种因素影响。公司始终坚持聚焦病理行业，多措并举抓好生产经营，保证信息披露 及时、准确，不断加强市值管理。 ...

Core Insights - The "2025 Overseas Listed Companies CFO Summit and CFO Top 100 Awards Ceremony" was successfully held in Shanghai, attracting over 100 guests from various stock markets to share experiences and discuss future trends [1] Group 1: Event Overview - The event was guided by the Shanghai Hongqiao Management Committee and involved multiple supporting institutions, including Ernst & Young, SoftBank China, and Gobi Partners [1] - The summit featured keynote speeches and roundtable discussions, focusing on the challenges and opportunities in international capital markets [3][4] Group 2: Keynote Speeches - Professor Li Ruoshan from Fudan University discussed the opportunities and challenges for Chinese companies going global, emphasizing the need for CFOs to enhance compliance awareness and governance structures [3] - Ernst & Young's partner, Mr. Tang Zhehui, highlighted the importance of "security, technology, and development" as strategic cores for the next five years amid global geopolitical tensions [6] Group 3: Roundtable Discussions - The "Consumer Retail" session focused on financial resilience and value reconstruction, with CFOs sharing practical experiences on store returns, inventory optimization, and AI applications [8] - The "Pharmaceutical and Medical" session discussed the hot topics and outlook for 2025, emphasizing Hong Kong as a crucial bridge for companies going global [10] - The "Going Global" session highlighted the evolving role of CFOs from financial controllers to strategic integrators and risk managers in international operations [12] - The "ESG and Capital Markets" session underscored the necessity of ESG compliance for companies, linking it directly to valuation and financing efficiency [14] Group 4: Awards and Recognition - The CFO Top 100 list was unveiled, reflecting the evolving expectations of CFO roles in the global capital market [16] - The founder and CEO of YaoDa, Mr. Zhang Jianfeng, emphasized the summit's role as a professional platform for CFOs to showcase and exchange ideas [18][24] - The launch of the "TOP100 CLUB" community plan aims to enhance collaboration and value creation among CFOs [22][28]

Group 1 - The company, Nanjing Qianjing Venture Capital Partnership, held 1,677,265 shares of Guangzhou Anbiping Pharmaceutical Technology Co., Ltd., accounting for 1.79% of the total share capital before the reduction plan [1] - The reduction plan involved Nanjing Qianjing intending to reduce its holdings by up to 1,677,265 shares through centralized bidding and block trading, which represents 1.79% of the company's total share capital [1] - As of December 3, 2025, Nanjing Qianjing had reduced its holdings by 174,922 shares, which is 0.19% of the total share capital, and the reduction plan period has expired [1][3] Group 2 - The reduction subject has no concerted actions with other parties [2] - The actual reduction complied with relevant laws and regulations, and the actual reduction was consistent with the previously disclosed reduction plan [5] - The reduction plan was fully implemented, and there were no violations of the reduction plan or other commitments [5]

（编辑 袁冠琳） 证券日报网讯 12月3日晚间，安必平发布公告称，南京乾靖创业投资合伙企业（有限合伙）于2025年9 月4日至12月3日以集中竞价方式累计减持公司股票174，922股，减持比例占公司总股本0.19%，减持计 划时间区间已届满。 ...

证券代码：688393 证券简称：安必平 公告编号：2025-052 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东的基本情况 广州安必平医药科技股份有限公司 本次减持计划实施前，南京乾靖创业投资合伙企业（有限合伙）（以下简称 "南京乾靖"）持有广州安必平医药科技股份有限公司（以下简称"公司"） 1,677,265 股股份，占公司总股本的比例为 1.79%，该等股份为南京乾靖于公司 首次公开发行并上市前取得的股份，且已于 2021 年 8 月 20 日解除限售后上市流 通。 股东减持股份计划时间届满暨减持股份结果公告 减持计划的实施结果情况 2025 年 8 月 14 日，公司披露了《广州安必平医药科技股份有限公司股东减 持股份计划公告》（公告编号：2025-033），南京乾靖拟通过集中竞价方式及大 宗交易方式减持所持有的公司股份不超过 1,677,265 股(含本数)，不超过公司目 前总股本的 1.79%。 2025 年 12 月 3 日，公司收到股东南京乾靖发来的《关于股份减持的告知函 ...

格隆汇12月3日丨安必平(688393.SH)公布，2025年12月3日，公司收到股东南京乾靖发来的《关于股份 减持的告知函》,减持计划期间南京乾靖以集中竞价的方式累计减持公司股票17.49万股，减持比例占公 司总股本0.19%。本次减持计划时间区间已届满。 ...

Group 1 - Recent collaboration between Anbiping (688393.SH) and CSPC Pharmaceutical Group (1093.HK) focuses on the development of C-MET companion diagnostics [1] - Anbiping will be responsible for the development of immunohistochemistry companion diagnostic products and the commercialization of IVD/CDx kits, enhancing clinical applications for cancer patients [2] - CSPC Pharmaceutical Group, established in 1997, has maintained double-digit growth in key operational metrics and is recognized for its innovative development in the pharmaceutical industry [3] Group 2 - CSPC has two national key laboratories and over 60 products with annual sales exceeding 100 million, covering APIs, chemical drugs, biological drugs, and functional foods [3] - Anbiping, founded in 2005, is the first listed company in China focusing on pathology diagnostics, with over 200 self-developed immunohistochemistry antibodies and advanced digital + AI-assisted diagnostic products [4] - Anbiping serves over 3,000 medical institutions nationwide through its comprehensive business model that includes tumor screening, pathology diagnosis, smart pathology, and pathology services [4]

Market Overview - On November 18, U.S. stock markets experienced a decline across all three major indices, with the Dow Jones Industrial Average and S&P 500 both falling for the fourth consecutive trading day [1][3] - The Dow Jones Industrial Average dropped by 1.07% to 46,091.74 points, while the S&P 500 fell by 0.83% to 6,617.32 points, and the Nasdaq index decreased by 1.21% to 22,432.85 points [3] Technology Sector - Major technology stocks saw collective declines, with Amazon down over 4%, Nvidia nearly 3%, Microsoft over 2%, and Tesla close to 2% [3] - Cloudflare reported global network issues that disrupted services for several major platforms, including X (formerly Twitter) and ChatGPT, leading to a nearly 3% drop in its stock price [2][3] Semiconductor Industry - The semiconductor sector faced a downturn, with the Philadelphia Semiconductor Index falling by 2.31%. Notable declines included MyWave Technology down nearly 6%, Micron Technology down over 5%, and AMD down over 4% [5] - SanDisk, a flash memory chip company, saw its stock plummet by over 10% during trading, although it had previously surged more than fivefold in price over the past three months [5] Energy Sector - Energy stocks generally rose, with Occidental Petroleum increasing nearly 2%, and ExxonMobil and ConocoPhillips both rising over 1% [3] Gold Sector - Gold stocks experienced widespread gains, with AngloGold up over 3%, Barrick Gold rising more than 2%, and both Kinross Gold and Eldorado Gold increasing over 1% [4]

Fundraising Overview - The company has completed the fundraising project named "Pathological Digitalization and Intelligent Application Development Project" and has utilized the raised funds as planned, achieving the main research and development goals [1][3] - The remaining funds from the project amount to 303,200 yuan, which will be permanently used to supplement the company's working capital for daily operations [3] Regulatory Compliance - According to the regulations of the Shanghai Stock Exchange, if the remaining fundraising amount (including interest income) is below 10 million yuan, the company is exempt from board review procedures and does not require a clear opinion from the sponsor institution or independent financial advisor [2]

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]